General

About Company

Kiniciti partners with companies to transform the cell and gene therapy ecosystem and deliver novel treatments to patients in need.

Industry

Sector :

Subsector :

founded date

01.01.2020

Number of employees

11-50

Last funding type

Undisclosed

IPO status

Private

Description

Kiniciti is a Welsh, Carson, Anderson & Stowe platform that provides resources, expertise, and capital to help life science companies scale and deliver compelling customer value. The company invests in opportunities with the potential to leverage technology and capabilities to drive transformational change and ensure that cell and gene therapies are delivered to patients in need. Kiniciti focuses on addressing bottlenecks, constraints, and inefficiencies in the development, manufacturing, and delivery of innovative therapies. The company is committed to making the promise of breakthrough CGT therapies a reality, ensuring that future treatments reach patients as quickly and cost-efficiently as possible. Kiniciti pursues partnerships in various areas, including cell sources, enabling technology platforms, process development and scale-up, source-to-patient delivery, and other solutions designed to fulfill the promise of breakthrough treatments while concurrently reducing costs to ensure affordable access for patients. Welsh, Carson, Anderson & Stowe committed a minimum of $250M to support companies primed to transform healthcare through their CGT offerings, and Kiniciti has a flexible remit to ensure that they invest in the right companies, with the right technology, at the right time.